BioCentury
ARTICLE | Company News

Neurogen, Aventis deal

January 5, 2004 8:00 AM UTC

NRGN received a $1 million milestone from AVE under the companies' 2001 deal to develop therapeutics against corticotrophin releasing factor ( CRF1). The payment was triggered by a preclinical milesto...